The findings, published in Cell Reports, show a new way ovarian cancer cells resist chemotherapy. Until now, cisplatin was mainly known for damaging DNA. The study reveals the drug also disrupts microtubules, the cell's internal scaffold, and that cancer cells adapt by changing this structure. Sachi Horibata of Michigan State University is one of the lead researchers and says the work explains how tumours adapt and later become resistant.
At the centre of the process is a protein called tubulin polymerization promoting protein 3, or TPPP3. The researchers found that cells with higher TPPP3 levels stabilise microtubules and resist cisplatin or carboplatin, while patients with lower TPPP3 levels lived longer and responded better to treatment.
In laboratory models, removing TPPP3 significantly restored sensitivity to cisplatin. Horibata describes TPPP3 as a protective shield for cancer cells: removing it weakens defenses and allows chemotherapy to work more effectively. Researchers now plan to develop drugs that target TPPP3 and to test whether it can serve as a biomarker; they will also study how this mechanism affects chemotherapy combinations and other cancer types.
Difficult words
- microtubule — small tube-like structures that support cell shapemicrotubules
- tubulin — protein that makes microtubules inside cells
- stabilise — make something stronger and less likely to change
- restore — bring back a previous condition or abilityrestored
- biomarker — a biological sign used to show disease
- adapt — change to fit new conditions
Tip: hover, focus or tap highlighted words in the article to see quick definitions while you read or listen.
Discussion questions
- How might drugs that target TPPP3 help people with ovarian cancer?
- Why would doctors want a biomarker such as TPPP3 for treatment decisions?
- What would you ask researchers studying how cancer cells become resistant to chemotherapy?
Related articles
Do low‑calorie sweeteners affect blood sugar and health?
Researchers reviewed trials and large studies on non‑nutritive sweeteners and found signals of worse blood sugar control and possible metabolic harm. They note questions about mechanisms, study limits, and a need for more trials.
Experimental vaccine gives lasting protection in mice against CCHF
A new mouse study reports an experimental vaccine that produced rapid protection and antibodies that lasted up to 18 months. Researchers say a booster strengthened and extended immune responses and plan manufacturing steps before human trials.
